ESTA enters the week with an interesting split: the stock has rallied 22% over the past month and Citigroup just lifted its price target by $16, yet short sellers have quietly rebuilt positions to a level well above the broader market average.
The most timely development came on July 8, when Citigroup raised its target from $76 to $92 — just $1 below the current price at $91.04 — while keeping its Neutral rating. That move is notable less for the upgrade that didn't happen and more for the magnitude of the catch-up: Citi's prior target, cut to $74 back in March, had badly lagged the stock's recovery. BTIG, by contrast, has been more constructive throughout, holding a Buy with a $90 target since May. Mizuho's Outperform with a $100 target, set in February, remains the most bullish flag on the Street. The consensus mean now clusters around $93, barely above spot — suggesting the Street has largely been chasing this rally rather than leading it.
Short positioning tells a more complicated story than the price action implies. Short interest runs at 13.6% of the free float — still elevated by any standard, and up about 7.7% on a 30-day basis, meaning shorts have been adding into this rally, not retreating. The official FINRA fortnightly figure (settlement date June 15) pegged shares short at 3.89 million, with days-to-cover at 7.1 — a meaningful cushion for an aggressive short. That said, the borrow market is not particularly stressed. Cost to borrow has fallen sharply this week to roughly 0.58%, down from near 0.90% at end-June. Availability has also loosened back to 93%, well off the multi-year tights seen earlier in the year when availability dropped below 1%. The ORTEX short score has hovered in the mid-70s all week — high relative to the universe, consistent with a stock that has a meaningful, durable short base rather than one in the middle of being squeezed out.
Options positioning leans bullish rather than cautious. The put/call ratio closed July 7 at 0.49, modestly above its 20-day mean of 0.44 but only 0.4 standard deviations above it — well within normal range. The directional shift over the past month is worth flagging, though: PCR ran below 0.30 through most of June, meaning the recent drift higher reflects a gradual accumulation of puts relative to calls as the stock has moved up. The 52-week high on PCR is 2.0, so the current reading is nowhere near defensive territory. Options traders are not hedging hard into the next print.
The ownership picture carries one flag worth watching. JW Asset Management — the largest institutional holder at roughly 9.8% of shares — was a consistent seller in May, offloading shares on at least five separate days between May 6 and May 28 at prices from $70 to $76. The stock has since moved to $91. Those sales now look early, but JW still holds 2.89 million shares. The founder, Juan Jose Chacon Quiros, also sold around 105,000 shares in early May for roughly $7.9 million. Net insider flow over the 90-day window is positive at approximately $33 million — but that aggregate is almost certainly distorted by stock awards; the actual cash-sale activity from major holders has been a source of supply into the rally.
Earnings land on August 5. The past two quarterly releases both produced modest one-day gains (around 1.5–2.0%) followed by five-day fades of 1–3%. With the stock near the top of the analyst target range and the short base remaining sticky despite a 22% one-month move, the August print becomes a key test of whether shorts trim or double down — and whether Citi's hesitation to move past Neutral reflects broader Street caution on the valuation at these levels.
See the live data behind this article on ORTEX.
Open ESTA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
